AnalystsRick BienkowskiRick Bienkowski's Stock Forecasts
AnalystsRick Bienkowski
Sectors:
Industries:
Analyst Ranking
Bottom 1%
#4972 out of 5014 analysts
Average Return
-32.94%
Win Rate
18%5 out of 28
Risk vs Reward
Poor
Good
Rick Bienkowski's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Crispr Therapeutics AgCRSP | +34.05% | $47.31 | $63.42 | 2022-05-10 - 2023-05-09 | Buy |
Beam Therapeutics IncBEAM | +19.85% | $22.27 | $26.69 | 2023-10-17 - 2024-10-16 | Strong Buy |
Legend Biotech CorpLEGN | +19.10% | $27.80 | $33.11 | 2025-05-14 - 2025-09-12 | Strong Buy |
Beam Therapeutics IncBEAM | +9.82% | $23.72 | $26.05 | 2023-08-29 - 2024-08-28 | Strong Buy |
Beam Therapeutics IncBEAM | +0.18% | $33.29 | $33.35 | 2022-05-09 - 2023-05-08 | Buy |
Rick Bienkowski Analyst Color
Get additional color on Rick Bienkowski's coverage of popular stocks
Rick Bienkowski's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Legend Biotech CorpLEGN | 3 | Strong Buy | $55.00 | +66.11% | Reiterates | 4 months ago |
Beam Therapeutics IncBEAM | 10 | Buy | $39.00 | +89.32% | Upgrades | 10 months ago |
Intellia Therapeutics IncNTLA | 7 | Strong Buy | $65.00 | N/A | Reiterates | a year ago |
Verve Therapeutics IncVERV | 3 | Hold | $22.00 | N/A | Reiterates | 2 years ago |
Editas Medicine IncEDIT | 6 | Strong Buy | $14.00 | N/A | Reiterates | 2 years ago |
Crispr Therapeutics AgCRSP | 4 | Buy | $107.00 | N/A | Maintains | 3 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.